Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2018 1
2019 2
2020 1
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year
Filters applied: . Clear all
Page 1
Preclinical Targeted α- and β--Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies.
Puttemans J, Dekempeneer Y, Eersels JL, Hanssens H, Debie P, Keyaerts M, Windhorst AD, van der Aa F, Lecocq Q, Breckpot K, Morgenstern A, Bruchertseifer F, Lahoutte T, Devoogdt N, D'Huyvetter M. Puttemans J, et al. Cancers (Basel). 2020 Apr 21;12(4):1017. doi: 10.3390/cancers12041017. Cancers (Basel). 2020. PMID: 32326199 Free PMC article.
Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
Dekempeneer Y, Bäck T, Aneheim E, Jensen H, Puttemans J, Xavier C, Keyaerts M, Palm S, Albertsson P, Lahoutte T, Caveliers V, Lindegren S, D'Huyvetter M. Dekempeneer Y, et al. Among authors: puttemans j. Mol Pharm. 2019 Aug 5;16(8):3524-3533. doi: 10.1021/acs.molpharmaceut.9b00354. Epub 2019 Jul 3. Mol Pharm. 2019. PMID: 31268724
The road to personalized myeloma medicine: Patient-specific single-domain antibodies for anti-idiotypic radionuclide therapy.
Puttemans J, Stijlemans B, Keyaerts M, Vander Meeren S, Renmans W, Fostier K, Debie P, Hanssens H, Rodak M, Pruszynski M, De Veirman K, Vanderkerken K, Lahoutte T, Morgenstern A, Bruchertseifer F, Devoogdt N, D'Huyvetter M. Puttemans J, et al. Mol Cancer Ther. 2021 Oct 19:molcanther.MCT-21-0220-A.2021. doi: 10.1158/1535-7163.MCT-21-0220. Online ahead of print. Mol Cancer Ther. 2021. PMID: 34667109